ASCO 2021 | ARTISTRY-2: Phase I/II study of nemvaleukin alfa in solid tumors

Nemvaleukin alfa is a novel engineered cytokine that selectively binds the IL-2 receptor to preferentially activate CD8+ T and natural killer cells with minimal expansion of regulatory T cells, designed for use as a cancer immunotherapy. In this interview, Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the selection of the recommended Phase II dose for subcutaneous nemvaleukin alfa in the ARTISTRY-2 study (NCT03861793) which is evaluating this novel agent in combination with pembrolizumab for patients with advanced solid tumors. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.